The association between Fibrosis index 4 and renal dysfuction in type 2 diabetes taking SGLT2 inhibitors

The association between Fibrosis index 4 and renal dysfuction in type 2 diabetes taking SGLT2 inhibitors - The association between Fibrosis index 4 and renal dysfuction in type 2 diabetes taking SGLT2 inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055471

Enrollment

130

Registered

2024-09-15

Start date

2024-08-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult type 2 diabetes patients who newry start SGLT2 inhibitors

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
Is there any differecnces in the occurence of renal dysfunction according to the FIB-4	—

Countries

Japan

Contacts

Public ContactKeisuke Takano

Tokyo Bay Urayasu Ichikawa Medical Center Department of Nephrology, Endocrinology and Diabetes

kt900928@gmail.com047-351-3101

Outcome results